RGB-286638: Preliminary Phase I data

Preliminary data from an ongoing, dose-escalation Phase I trial in 25 patients showed that IV RGB-286638 was well tolerated at doses of up to 80 mg/day. The MTD was exceeded at 160 mg RGB-286638 and p...